$ANIP

Bristol-Myers Squibb (BMY) reported Q2 revenue of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenue of $2.47B, missing estimates. Merck (MRK) reported $16.61B revenue, up 5.1% YoY, beating estimates. ANI Pharmaceuticals (ANIP) reported $266M revenue, up 25.9% YoY, with mixed results. Stocks reacted variably post-earnings.

ANI Pharma reported positive phase 4 trial results for Iluvien in treating non-infectious uveitis. The study met both primary endpoints, showing improvements in patients' conditions. According to the company, the findings demonstrate the drug's effectiveness in this area.

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

Ocular Therapeutix (OCUL) and ANI Pharmaceuticals (ANIP) stocks fell 6.7% and 4.3%, respectively, as healthcare sector sentiment weakened due to CMS canceling Affordable Care Act coverage for 760,000 people and clawing back $2.2B in subsidies. OCUL is down 13.8% YTD and 36.7% from its 52-week high.

ANI Pharmaceuticals (ANIP) received FDA approval for its generic Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product, a generic version of Afinitor Disperz, expands ANI's generics portfolio. The company expects to launch at least 15 new generic products this year. U.S. annual sales for the approved product were approximately $123 million, according to IQVIA data cited by ANI. ANIP's stock closed at $77.91 on Tuesday, with pre-market trading at $78.99.

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

ANI Pharmaceuticals Inc. (ANIP) filed an Initial Statement of Beneficial Ownership (Form 3) on August 19, 2026, disclosing a director's ownership of securities. The company is a diversified biopharmaceutical firm focused on rare disease treatments and generic pharmaceuticals, with segments including Rare Disease, Brands, and Generics.

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., August 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Compa